Bioreactors Market Outlook 2026-2035 - Featuring Profiles of 3 Leading Companies: Sartorius, Thermo Fisher Scientific, and Danaher

Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Bioreactors Market Opportunity, Growth Drivers, Industry Trend Analysis and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering.

Global Bioreactors Market to Reach USD 38.9 Billion by 2035 as Advanced Biomanufacturing Expands

The global bioreactors market was valued at USD 13.8 billion in 2025 and is projected to reach USD 38.9 billion by 2035, expanding at a compound annual growth rate (CAGR) of 11.2%. Market growth is being supported by continued expansion across the pharmaceutical and biotechnology industries, increasing biologics production, and technological advancements in bioreactor systems.

Rising demand for vaccines, monoclonal antibodies, recombinant proteins, gene therapies, and cell-based treatments is accelerating the adoption of scalable bioreactor technologies. The growing prevalence of chronic and rare diseases, combined with increased investment in personalized medicine and advanced therapies, is further strengthening the global bioreactors market outlook.

Advances in genetic engineering, regenerative medicine, biosimilars, and orphan drug development are creating additional requirements for efficient, reliable, and regulatory-compliant biomanufacturing infrastructure. Manufacturers are increasingly investing in single-use bioreactors, automated production platforms, modular systems, and real-time process monitoring to improve scalability, reduce operational complexity, and maintain consistent product quality.

The reusable bioreactor segment generated USD 10 billion in 2025. These systems remain widely adopted in large-scale biopharmaceutical manufacturing due to their durability, operational versatility, and suitability for repeated production cycles. Reusable bioreactors support complex, high-volume processes in which manufacturers must maintain productivity, process control, and stringent quality standards across multiple batches.

The mammalian cell segment accounted for USD 10.3 billion in 2025, reflecting its central role in the production of complex biologics. Mammalian cell culture is extensively used for monoclonal antibodies, vaccines, recombinant proteins, and other advanced therapeutic products. Demand for precisely controlled bioreactor environments continues to rise because mammalian cell performance depends on carefully managed temperature, pH, oxygen concentration, nutrient availability, and other critical process parameters.

The U.S. bioreactors market was valued at USD 4.7 billion in 2025. Growth is being driven by the country's established pharmaceutical and biotechnology sectors, significant investment in biologics manufacturing, and increasing adoption of personalized medicine. Expanding development pipelines for vaccines, monoclonal antibodies, gene therapies, and cell therapies are also encouraging U.S. manufacturers to increase production capacity and implement advanced bioprocessing technologies.

Leading companies operating in the global bioreactors market include Danaher Corporation, Thermo Fisher Scientific Inc., Sartorius AG, Merck KGaA, Eppendorf Group, GEA Group Aktiengesellschaft, Altrad Group, Cellexus, CerCell A/S, Donaldson Company, Inc., BaiLun Biotechnology Co., Ltd, Bbi-biotech, Esco Micro Pte. Ltd., and PBS Biotech, Inc.

Market participants are prioritizing global capacity expansion, research and development, automation, and next-generation single-use and modular bioreactor platforms. Strategic partnerships, acquisitions, and supply chain initiatives are helping companies strengthen their regional presence, diversify product portfolios, and secure access to critical materials and components.

Digital bioprocessing is also becoming an important competitive focus. Companies are integrating artificial intelligence-driven process control, advanced analytics, and real-time monitoring systems to increase productivity, enhance operational efficiency, and support compliance with stringent regulatory requirements. These investments are expected to reinforce the role of bioreactors as essential infrastructure for commercial-scale biologics and advanced therapy manufacturing through 2035.

Comprehensive Global Bioreactors Market Analysis and Forecast Includes:

Key Attributes:

Key Topics Covered:

Chapter 1 Methodology and Scope

1.1 Market scope and definition

1.2 Research design

1.2.1 Research approach

1.2.2 Data collection methods

1.3 Data mining sources

1.3.1 Global

1.3.2 Regional/Country

1.4 Base estimates and calculations

1.4.1 Base year calculation

1.4.2 Key trends for market estimation

1.5 Primary research and validation

1.5.1 Primary sources

1.6 Forecast model

1.7 Research assumptions and limitations

Chapter 2 Executive Summary

2.1 Industry 360-degree synopsis

2.2 Key market trends

2.2.1 Regional trends

2.2.2 Product type trends

2.2.3 Cell trends

2.2.4 Molecule trends

2.2.5 Usage trends

2.2.6 Material trends

2.2.7 Size trends

2.2.8 End use trends

2.3 CXO perspectives: Strategic imperatives

2.3.1 Key decision points for industry executives

2.3.2 Critical success factors for market players

2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis

3.2 Industry impact forces

3.2.1 Growth drivers

3.2.1.1 Growing pharmaceutical and biotechnology industry

3.2.1.2 Technological advancements in bioreactors

3.2.1.3 Growing focus on orphan drug development

3.2.1.4 Rising demand for personalized medicines

3.2.2 Industry pitfalls and challenges

3.2.2.1 Low capacity of single-use bioreactors

3.2.2.2 Concerns regarding extractables and/or leachables

3.2.3 Market opportunities

3.2.3.1 Precision fermentation for novel healthcare applications

3.3 Growth potential analysis

3.4 Regulatory landscape

3.4.1 North America

3.4.2 Europe

3.4.3 Asia-Pacific

3.4.4 Latin America

3.4.5 Middle East and Africa

3.5 Technological advancements

3.5.1 Current technological trends

3.5.2 Emerging technologies

3.6 Pricing analysis, 2024

3.7 Future market trends

3.8 Porter's analysis

3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

4.1 Introduction

4.2 Company market share analysis

4.3 Company matrix analysis

4.4 Competitive analysis of major market players

4.5 Competitive positioning matrix

4.6 Key developments

4.6.1 Mergers and acquisitions

4.6.2 Partnerships and collaborations

4.6.3 New product launches

4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, by Product type, 2022-2035 ($ Mn)

5.1 Key trends

5.2 Single-use (Plastic)

5.3 Reusable

Chapter 6 Market Estimates and Forecast, by Cell, 2022-2035 ($ Mn)

6.1 Key trends

6.2 Mammalian cells

6.3 Bacterial cells

6.4 Yeast cells

6.5 Other cells

Chapter 7 Market Estimates and Forecast, by Molecule, 2022-2035 ($ Mn)

7.1 Key trends

7.2 Monoclonal antibodies

7.3 Vaccines

7.4 Recombinant proteins

7.5 Stem cells

7.6 Gene therapy

7.7 Other molecules

Chapter 8 Market Estimates and Forecast, by Usage, 2022-2035 ($ Mn)

8.1 Key trends

8.2 Developmental, pre-clinical & clinical

8.3 Commercial production

Chapter 9 Market Estimates and Forecast, by Materials, 2022-2035 ($ Mn)

9.1 Key trends

9.2 Stainless steel

9.3 Glass

9.4 Single-use

Chapter 10 Market Estimates and Forecast, by Size, 2022-2035 ($ Mn)

10.1 Key trends

10.2 Less than 500 L

10.3 501-5,000 L

10.4 More than 5,000 L

Chapter 11 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)

11.1 Key trends

11.2 R&D organizations

11.3 Biopharma manufacturers

11.4 Contract manufacturing organizations (CMOs)

Chapter 12 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)

12.1 Key trends

12.2 North America

12.2.1 U.S.

12.2.2 Canada

12.3 Europe

12.3.1 Germany

12.3.2 UK

12.3.3 France

12.3.4 Spain

12.3.5 Italy

12.3.6 Netherlands

12.4 Asia-Pacific

12.4.1 China

12.4.2 India

12.4.3 Japan

12.4.4 Australia

12.4.5 South Korea

12.5 Latin America

12.5.1 Brazil

12.5.2 Mexico

12.5.3 Argentina

12.6 Middle East and Africa

12.6.1 Saudi Arabia

12.6.2 South Africa

12.6.3 UAE

Chapter 13 Company Profiles

13.1 Altrad Group

13.2 BaiLun Biotechnology Co., Ltd

13.3 Bbi-biotech

13.4 Cellexus

13.5 CerCell A/S

13.6 Danaher Corporation

13.7 Donaldson Company, Inc

13.8 Eppendorf Group

13.9 Esco Micro Pte. Ltd.

13.10 GEA Group Aktiengesellschaft

13.11 Getinge AB

13.12 Merck KGaA

13.13 PBS Biotech, Inc.

13.14 Sartorius AG

13.15 Thermo Fisher Scientific Inc.

For more information about this report visit https://www.researchandmarkets.com/r/hoho4k

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.